Bayer Aktiengesellschaft (BAYZF)
OTCMKTS · Delayed Price · Currency is USD
31.07
+0.32 (1.04%)
Oct 31, 2025, 4:00 PM EDT
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 10.74B EUR in the quarter ending June 30, 2025, a decrease of -3.63%. This brings the company's revenue in the last twelve months to 46.17B, down -1.99% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
46.17B EUR
Revenue Growth
-1.99%
P/S Ratio
0.56
Revenue / Employee
502.63K EUR
Employees
91,864
Market Cap
30.54B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| China New Energy Group Co. | 12.51M |
| Northwest Biotherapeutics | 1.09M |
Bayer Aktiengesellschaft News
- 3 days ago - Bayer's Monsanto must pay $185 million after Washington court restores chemical leak verdict - Yahoo
- 4 days ago - Bayer and Luke Bryan Mark 10 Years of Fighting Hunger with YourUpdateTV - GlobeNewsWire
- 9 days ago - Bayer Wins FDA Approval for Menopause Drug Treating Hot Flashes - Financial Post
- 9 days ago - US FDA approves Bayer's menopause relief drug - Reuters
- 9 days ago - Bayer's Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause - Business Wire
- 12 days ago - Top 3 Health Care Stocks You'll Regret Missing In October - Benzinga
- 13 days ago - Bayer Leverkusen vs PSG: Head-to-head, match preview, predicted lineups and score prediction - Business Upturn
- 24 days ago - BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers - Nasdaq